



Indraprastha Medical Corporation Limited

(Indraprastha Apollo Hospitals)

Regd. Office : Sarita Vihar, Delhi-Mathura Road, New Delhi – 110 076 (India)

Corporate Identity Number : L24232DL1988PLC030958

Phone:91-11-26925858,26925801,Fax: 91-11-26823629

E-mail: imcl@apollohospitals.com, Website : <https://www.apollohospitals.com/delhi/>



Ref: IMCL/CS/BM/2025

3rd February, 2025

The Manager
Listing Department
BSE Limited Phiroze Jeejeebhoy
Towers Dalal Street, Mumbai,
Maharashtra - 400001
Scrip Code: 532150

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra East,
Mumbai, Maharashtra - 400051
Symbol: INDRAMEDCO

Re: Outcome of the Board Meeting held on 3rd February, 2025 – Unaudited Financial Results for the quarter and nine months ended 31st December, 2024

Dear Sir,

This is to inform that the Board of Directors of the Company has, at its meeting held on Monday, 3rd February, 2025 (i.e. today), inter-alia, considered and approved the Un-audited Financial Results of the Company for the quarter & nine months ended 31st December, 2024, along with the Limited Review Report of the Statutory Auditor.

We are enclosing herewith the Un-audited Financial Results for the quarter and nine months ended 31st December, 2024, along with the Limited Review Report of the Statutory Auditor – **Annexure A.**

The Board meeting commenced at 3.15 p.m. and ended at 4.35 p.m.

This is for your information and record.

Thanking You,

Yours sincerely,

For Indraprastha Medical Corporation Limited

Priya Ranjan
AVP – Corporate Affairs & Legal
(Company Secretary & Compliance Officer)

Encl. as above

Limited Review Report on Unaudited Quarterly and Year to Date Results

To the Board of Directors of Indraprastha Medical Corporation Limited

1. We have reviewed the accompanying statement of unaudited financial results of **Indraprastha Medical Corporation Limited** ("the Company") for the quarter ended 31 December 2024 and year to date results for the period 01 April 2024 to 31 December 2024 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India ("the SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. This Statement which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant Rules issued thereunder; and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **S.N. Dhawan & CO LLP**

Chartered Accountants

Firm Registration No.: 000050N/N500045



Bhaskar Sen

Partner

Membership No.: 096985

UDIN.: 25096985BMOPVA6892



Place: New Delhi

Date: 03 February 2025

Statement of Unaudited Financial Results for the Quarter and Nine-months ended 31st December, 2024


S. No.	Particulars	Amount (Rs. in crore)					
		Quarter ended			Nine-months ended		Year ended
		31.12.2024 (Unaudited)	30.09.2024 (Unaudited)	31.12.2023 (Unaudited)	31.12.2024 (Unaudited)	31.12.2023 (Unaudited)	31.03.2024 (Audited)
1	Revenue from operations	324.93	349.82	306.46	1022.61	929.97	1244.70
2	Other income	5.13	6.05	4.27	16.30	12.00	16.89
3	Total income	330.06	355.87	310.73	1038.91	941.97	1261.59
4	Expenses						
	a) Cost of materials consumed	56.18	56.23	50.52	171.34	161.69	217.19
	b) Employee benefits expense	72.18	71.61	66.48	210.38	196.82	261.61
	c) Professional charges to doctors	86.04	91.16	77.05	267.87	231.67	311.79
	d) Finance costs	1.58	1.59	0.87	4.78	2.50	4.06
	e) Depreciation and amortisation expense	11.21	11.17	10.03	33.42	29.87	40.08
	f) Other expenses	58.34	67.18	65.11	190.07	194.87	260.75
	Total expenses	285.53	298.94	270.06	877.86	817.42	1095.48
5	Profit before exceptional items and tax	44.53	56.93	40.67	161.05	124.55	166.11
6	Exceptional items	-	-	-	-	-	-
7	Profit before tax (PBT)	44.53	56.93	40.67	161.05	124.55	166.11
8	Tax expense						
	Current tax	11.87	15.20	11.68	42.28	33.86	43.03
	Deferred tax	(0.15)	(0.67)	(0.45)	(1.21)	(2.10)	(0.88)
9	Profit for the period after tax (PAT)	32.81	42.40	29.44	119.98	92.79	123.96
10	Other comprehensive income						
	(i) Items that will not be reclassified to profit or loss	(0.15)	(1.60)	1.94	0.89	1.19	2.47
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.04	0.40	(0.49)	(0.22)	(0.30)	(0.62)
	Total other comprehensive income (Net of tax expenses)	(0.11)	(1.20)	1.45	0.67	0.89	1.85
11	Total comprehensive income for the period	32.70	41.20	30.89	120.65	93.68	125.81
12	Paid-up equity share capital (Face value Rs. 10/- each)	91.67	91.67	91.67	91.67	91.67	91.67
13	Reserves (excluding Revaluation Reserves) as shown in the audited balance sheet of previous year						386.09
14	Earnings per share Basic and Diluted (Rs.) - Not Annualised	3.58	4.63	3.21	13.09	10.12	13.52

Notes:

- The above financial results were reviewed by the Audit Committee and have been approved by the Board of Directors at their meeting held on 3rd February, 2025.
- The Company operates in a single segment i.e. Healthcare and hence, does not have any additional disclosures to be made under Ind AS 108 on Operating Segments.
- The Company does not have any subsidiary/associate/joint venture company(ies), as on 31st December, 2024.
- Previous year/period figures have been regrouped / rearranged wherever necessary.

Place : New Delhi
Date : 3rd February, 2025




Shivakumar Pattabhiraman
(Managing Director)
DIN: 08570283